27.03.2012 – 08:02 Astellas Pharma Europe LimitedAstellas Files Regulatory Submission for EC905 - A New Fixed Dose Combination Treatment for Male LUTS Staines, England (ots/PRNewswire) - ASTELLAS PHARMA EUROPE Ltd., the European subsidiary of Tokyo - based Astellas Pharma Inc. today announced the submission of a Market Authorisation Application for EC905 in the Netherlands. This application for approval is the first step of the European-wide mutual recognition ... more
30.08.2011 – 09:04 Astellas Pharma Europe LimitedAstellas Pharma Inc.: Announcement of Regulatory Submission for Mirabegron (YM178), a Treatment for Overactive Bladder, in U.S. and Europe Staines, England (ots/PRNewswire) - Astellas Pharma Inc. [http://www.astellas.com/en/corporate ] today announced the submission of a New Drug Application and Market Authorisation Application for mirabegron (generic name / code name: YM178) to the U.S. Food and Drug Administration and the European Medicines Agency. ... more